Cargando…

Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting

PURPOSE: The aim of the present study was to evaluate changes of best corrected visual acuity (BCVA), retinal nerve fiber layer thickness (RNFL), total macular volume (TMV), intraocular pressure (IOP) and central retinal thickness (CRT) after intravitreal injection of ranibizumab, bevacizumab and af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lüke, Jan Niklas, Alquoqa, Hamdi, Alsamman, Ahmad, Aljabary, Bayan, Schaub, F., Heindl, L. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902313/ https://www.ncbi.nlm.nih.gov/pubmed/35781595 http://dx.doi.org/10.1007/s10792-022-02383-6

Ejemplares similares

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
por: Bulirsch, Louisa Maria, et al.
Publicado: (2022)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting
por: Rübsam, Anne, et al.
Publicado: (2022)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta, Hemal, et al.
Publicado: (2020)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021)

Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD
por: Hatz, Katja, et al.
Publicado: (2022)

Relationship Between Drusen Height and OCT Biomarkers of Atrophy in Non-Neovascular AMD
por: Au, Adrian, et al.
Publicado: (2022)

Choroidal Changes After Anti-VEGF Therapy in AMD Eyes With Different Types of Macular Neovascularization Using Swept-Source OCT Angiography
por: Shen, Mengxi, et al.
Publicado: (2023)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies
por: Clearkin, Louis, et al.
Publicado: (2019)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes
por: Arrigo, Alessandro, et al.
Publicado: (2021)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner, Faye, et al.
Publicado: (2019)

Polarisation-sensitive OCT is useful for evaluating retinal pigment epithelial lesions in patients with neovascular AMD
por: Schütze, Christopher, et al.
Publicado: (2016)

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

Swept-Source OCT Angiographic Characteristics of Treatment-Naïve Nonexudative Macular Neovascularization in AMD Prior to Exudation
por: Shen, Mengxi, et al.
Publicado: (2021)

Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
por: Zhang, Zhao, et al.
Publicado: (2022)

Longitudinal Higher-Order OCT Assessment of Quantitative Fluid Dynamics and the Total Retinal Fluid Index in Neovascular AMD
por: Ehlers, Justis P., et al.
Publicado: (2021)

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial
por: Heier, Jeffrey S., et al.
Publicado: (2022)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
por: Khanna, Saira, et al.
Publicado: (2019)

The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD
por: Khan, Adnan H., et al.
Publicado: (2021)

Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
por: Carrasco, Joao, et al.
Publicado: (2019)

Automated deep learning-based AMD detection and staging in real-world OCT datasets (PINNACLE study report 5)
por: Leingang, Oliver, et al.
Publicado: (2023)

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis
por: Wu, Mingxing, et al.
Publicado: (2017)

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to traumatic choroidal rupture
por: Barth, T., et al.
Publicado: (2019)

A Comparison Among Different Automatically Segmented Slabs to Assess Neovascular AMD using Swept Source OCT Angiography
por: Parravano, Mariacristina, et al.
Publicado: (2019)

Real World Data Comparison of Standard Care vs SDM Laser Vision Protection Therapy for Prevention of Neovascular AMD
por: Luttrull, Jeffrey K, et al.
Publicado: (2022)

Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway
por: Reitan, Gudrun, et al.
Publicado: (2023)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Mechanisms of FH Protection Against Neovascular AMD
por: Borras, Céline, et al.
Publicado: (2020)

The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment
por: Faatz, Henrik, et al.
Publicado: (2019)

The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes
por: Butt, Thomas, et al.
Publicado: (2015)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

Discontinuation of treatment and retreatment of neovascular age-related macular degeneration in the real-world: Bundang AMD cohort study report 5
por: Cho, Soo Chang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n1rppnjjji6t85a0i7itiv597d